澳大利亚CSL公司（CSL.AX）周一宣布，任命临时首席执行官戈登·内勒（Gordon Naylor）为明年3月起任职的董事长。这是该公司在任命葛兰素史克（GSK.L）高管黛博拉·沃特豪斯（Deborah Waterhouse）为首位女性首席执行官几天后，进行的最新领导层变动。
Australia's CSL (CSL.AX) on Monday named interim chief Gordon Naylor as chair from March next year, the latest leadership shake-up days after naming GSK (GSK.L) executive Deborah Waterhourse as its first female CEO.
自2月以来，内勒一直担任CSL的临时负责人。此前，在前任首席执行官保罗·麦肯齐（Paul McKenzie）因投资者对这家生物技术巨头股价下跌的担忧而突然离职后，内勒接管了公司。
Naylor has led CSL on an interim basis since February, following the surprise exit of former CEO Paul McKenzie amid investor concerns over the biotechnology giant's falling shares.
CSL曾是澳大利亚市值最高的上市公司，也是市场宠儿，但近期遭遇了一系列盈利和营收预期下调，并宣布了裁员3000人的计划，引发了抛售潮，导致其过去一年市值蒸发了数十亿美元。
Once Australia's most valuable listed company and a market favourite, CSL suffered a series of earnings and revenue downgrades and announced plans to cut 3,000 jobs, triggering selloffs that wiped billions of dollars from its market value over the past year.
Global X ETFs高级ETF策略师马克·乔库姆（Marc Jocum）表示：“CSL的领导层格局终于明朗，戈登·内勒升任董事长在关键时刻提供了连续性。”
"CSL's leadership picture is finally coming into focus, and Gordon Naylor's elevation to chair provides continuity at a critical juncture," said Marc Jocum, senior ETF strategist at Global X ETFs.
他补充说，内勒在CSL战略重置中的角色及其对公司的了解，应能帮助即将上任的首席执行官黛博拉·沃特豪斯应对挑战，将新的高管领导层与经验丰富的董事长结合起来。
Naylor's role in CSL's strategic reset and his knowledge of the company should help incoming CEO Deborah Waterhouse tackle its challenges, combining new executive leadership with an experienced chair, he added.
现任董事长布莱恩·麦克纳米（Brian McNamee）在担任该职位八年多后，将于2027年3月31日从CSL董事会退休。他此前曾于1990年至2013年担任首席执行官兼董事总经理。
Current chair Brian McNamee will retire from CSL's board on March 31, 2027, after more than eight years in the role. He previously served as CEO and managing director from 1990 to 2013.
CSL股价收盘下跌0.8%，报195.14澳元，与医疗保健子指数（.AXHJ）0.5%的跌幅基本一致。
CSL shares closed 0.8% lower at A$195.14, broadly in line with a 0.5% decline in the healthcare sub-index (.AXHJ).